On March 10, 2025, NKGen Biotech Inc. entered into a $5 million convertible loan agreement with AlpineBrook Capital, with an initial $1 million advance and a 12% interest rate, to repay existing debt. The agreement includes issuing shares and warrants to the lender, convertible at $0.25 per share.